Search hospitals > Michigan > Chelsea
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Claim this profileChelsea, Michigan 48118
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
205 reported clinical trials
7 medical researchers
Summary
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is a medical facility located in Chelsea, Michigan. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is involved with conducting 205 clinical trials across 359 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Tareq Al BaghdadiGenesys Hurley Cancer Institute8 years of reported clinical research
Expert in Skin Cancer
Expert in Cancer
73 reported clinical trials
130 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital2 years of reported clinical research
Expert in Skin Cancer
Expert in Lung Cancer
51 reported clinical trials
104 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibGenesys Hurley Cancer Institute6 years of reported clinical research
Expert in Skin Cancer
Studies Multiple Myeloma
38 reported clinical trials
105 drugs studied
Clinical Trials running at Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Breast Cancer
Lung Cancer
Skin Cancer
Breast cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Multiple Myeloma
Stomach Cancer
Esophageal Adenocarcinoma
Bladder Cancer
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital?
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is a medical facility located in Chelsea, Michigan. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is involved with conducting 205 clinical trials across 359 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.